Literature DB >> 24131974

Variants of unknown significance in BRCA testing: impact on risk perception, worry, prevention and counseling.

S Richter1, I Haroun, T C Graham, A Eisen, A Kiss, E Warner.   

Abstract

BACKGROUND: Sequence-based BRCA testing can identify variants of unknown significance (VUS). Relatively little is known about how well a test outcome of VUS is understood by patients and referring physicians, and whether genetic counselors have an interest in the development of VUS management guidelines.
DESIGN: Self-administered questionnaires were completed by 36 VUS counselees, 75 women with a BRCA mutation and 33 with no mutation found (NMF). We also surveyed 24 genetic counselors and 22 referring family physicians.
RESULTS: One-third of VUS failed to recall the clinical significance of their result. Incorrect recall was significantly higher among VUS with high-school-only education (70% versus 19%, P = 0.02). Risk perception, cancer worry and uptake of surveillance and risk-reducing surgeries among VUS counselees were more similar to NMF than to mutation carriers. Genetic counselors accurately predicted the difficulties counselees would have with a VUS result and identified the need for VUS management guidelines. Referring physicians unanimously stated that genetic testing was indicated for unaffected siblings of VUS carriers.
CONCLUSIONS: While VUS seems to be correctly perceived by counselees as more similar to NMF than to a pathogenic mutation, miscomprehension of VUS is more common, particularly in counselees with lower education. VUS-related educational interventions for both VUS counselees and their referring physicians are needed. We encourage the development of national VUS-related guidelines for genetic counselors.

Entities:  

Keywords:  BRCA1; BRCA2; breast cancer; variants; variants of unknown significance

Mesh:

Substances:

Year:  2013        PMID: 24131974     DOI: 10.1093/annonc/mdt312

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  42 in total

1.  Genetic counselors' practices and confidence regarding variant of uncertain significance results and reclassification from BRCA testing.

Authors:  C L Scherr; N M Lindor; T L Malo; F J Couch; S T Vadaparampil
Journal:  Clin Genet       Date:  2015-02-26       Impact factor: 4.438

2.  Clinical Variant Classification: A Comparison of Public Databases and a Commercial Testing Laboratory.

Authors:  William Gradishar; KariAnne Johnson; Krystal Brown; Erin Mundt; Susan Manley
Journal:  Oncologist       Date:  2017-04-13

3.  Analysis of BRCA1/2 mutation spectrum and prevalence in unselected Chinese breast cancer patients by next-generation sequencing.

Authors:  Guoli Li; Xinwu Guo; Lili Tang; Ming Chen; Xipeng Luo; Limin Peng; Xunxun Xu; Shouman Wang; Zhi Xiao; Wenjun Yi; Lizhong Dai; Jun Wang
Journal:  J Cancer Res Clin Oncol       Date:  2017-06-29       Impact factor: 4.553

Review 4.  Epidemiology of Patients with Ovarian Cancer with and Without a BRCA1/2 Mutation.

Authors:  Elisabete Weiderpass; Jerzy E Tyczynski
Journal:  Mol Diagn Ther       Date:  2015-12       Impact factor: 4.074

Review 5.  Family-Specific Variants and the Limits of Human Genetics.

Authors:  Brian H Shirts; Colin C Pritchard; Tom Walsh
Journal:  Trends Mol Med       Date:  2016-10-11       Impact factor: 11.951

6.  From the laboratory to the clinic: sharing BRCA VUS reclassification tools with practicing genetics professionals.

Authors:  Bianca M Augusto; Paige Lake; Courtney L Scherr; Fergus J Couch; Noralane M Lindor; Susan T Vadaparampil
Journal:  J Community Genet       Date:  2017-11-09

7.  Physician interpretation of variants of uncertain significance.

Authors:  Sarah K Macklin; Jessica L Jackson; Paldeep S Atwal; Stephanie L Hines
Journal:  Fam Cancer       Date:  2019-01       Impact factor: 2.375

Review 8.  Living laboratory: whole-genome sequencing as a learning healthcare enterprise.

Authors:  M Angrist; L Jamal
Journal:  Clin Genet       Date:  2014-09-06       Impact factor: 4.438

Review 9.  Intensified surveillance for early detection of breast cancer in high-risk patients.

Authors:  Ulrich Bick
Journal:  Breast Care (Basel)       Date:  2015-02       Impact factor: 2.860

10.  A Novel von Hippel Lindau Gene Intronic Variant and Its Reclassification from VUS to Pathogenic: the Impact on a Large Family.

Authors:  A Sexton; L Rawlings; G McKavanagh; K Simons; I Winship
Journal:  J Genet Couns       Date:  2015-09-02       Impact factor: 2.537

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.